Mast cells, mastocytosis, and related disorders

New England Journal of Medicine

Volumn 373, Issue 2, 2015, Pages 163-172

  Theoharides, Theoharis C ^a   Valent, Peter ^c   Akin, Cem ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; CETIRIZINE; CLADRIBINE; CROMOGLYCATE DISODIUM; CYPROHEPTADINE; DASATINIB; DIPHENHYDRAMINE; FAMOTIDINE; FEXOFENADINE; HYDROXYZINE; IMATINIB; KETOTIFEN; LORATADINE; METHYLPREDNISOLONE; MONTELUKAST; PROCHLORPERAZINE; RANITIDINE; RUPATADINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTASE; ZILEUTON; HISTAMINE H1 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PROTEIN KINASE INHIBITOR;

ABDOMINAL CRAMP; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BONE MARROW BIOPSY; BONE MARROW TRANSPLANTATION; CELL ACTIVATION; CELL COUNT; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; COMORBIDITY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC TEST; DIARRHEA; DIFFERENTIAL DIAGNOSIS; ENZYME BLOOD LEVEL; GENE MUTATION; HEADACHE; HEARTBURN; HOT FLUSH; HUMAN; IMMUNOHISTOCHEMISTRY; MAST CELL; MASTOCYTOSIS; NAUSEA; PATHOPHYSIOLOGY; PREVALENCE; PRIMARY CLONAL MAST CELL DISORDER; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN DEFECT; STRUCTURE ACTIVITY RELATION; SYSTEMIC MASTOCYTOSIS; ULTRAVIOLET B RADIATION; URTICARIA PIGMENTOSA; ALGORITHM; PHYSIOLOGY; SECRETION (PROCESS);

ALGORITHMS; DIAGNOSIS, DIFFERENTIAL; EPINEPHRINE; HISTAMINE H1 ANTAGONISTS; HUMANS; LEUKOTRIENE ANTAGONISTS; MAST CELLS; MASTOCYTOSIS; PROTEIN KINASE INHIBITORS;

EID: 84935119657     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1409760     Document Type: Review

References (75)

1. Galli SJ, Borregaard N, Wynn TA. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol 2011; 12: 1035-44.
2. Rivera J, Fierro NA, Olivera A, Suzuki R. New insights on mast cell activation via the high affinity receptor for IgE. Adv Immunol 2008; 98: 85-120.
3. Donelan J, Boucher W, Papadopoulou N, et al. Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci U S A 2006; 103: 7759-64.
4. Gagari E, Tsai M, Lantz CS, Fox LG, Galli SJ. Differential release of mast cell interleukin-6 via c-kit. Blood 1997; 89: 2654-63.
5. Theoharides TC, Zhang B, Kempuraj D, et al. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci U S A 2010; 107: 4448-53.
6. Theoharides TC, Alysandratos KD, Angelidou A, et al. Mast cells and inflammation. Biochim Biophys Acta 2012; 1822: 21-33.
7. Migalovich-Sheikhet H, Friedman S, Mankuta D, Levi-Schaffer F. Novel identified receptors on mast cells. Front Immunol 2012; 3: 238.
8. Abraham SN, St John AL. Mast cellorchestrated immunity to pathogens. Nat Rev Immunol 2010; 10: 440-52.
9. Fux M, Pecaric-Petkovic T, Odermatt A, et al. IL-33 is a mediator rather than a trigger of the acute allergic response in humans. Allergy 2014; 69: 216-22.
10. Enoksson M, Lyberg K, Möller-Westerberg C, Fallon PG, Nilsson G, Lunderius-Andersson C. Mast cells as sensors of cell injury through IL-33 recognition. J Immunol 2011; 186: 2523-8.
11. Drube S, Heink S, Walter S, et al. The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. Blood 2010; 115: 3899-906.
12. Olszewski MB, Groot AJ, Dastych J, Knol EF. TNF trafficking to human mast cell granules: mature chain-dependent endocytosis. J Immunol 2007; 178: 5701-9.
13. Nakae S, Suto H, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cells enhance T cell activation: importance of mast cellderived TNF. Proc Natl Acad Sci U S A 2005; 102: 6467-72.
14. Zhang B, Asadi S, Weng Z, Sismanopoulos N, Theoharides TC. Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions. PLoS One 2012; 7(12): e49767.
15. Skokos D, Botros HG, Demeure C, et al. Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. J Immunol 2003; 170: 3037-45.
16. Bryniarski K, Ptak W, Jayakumar A, et al. Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity. J Allergy Clin Immunol 2013; 132: 170-81.
17. Dudeck A, Suender CA, Kostka SL, von Stebut E, Maurer M. Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function. Eur J Immunol 2011; 41: 1883-93.
18. Kenna TJ, Brown MA. The role of IL-17-secreting mast cells in inflammatory joint disease. Nat Rev Rheumatol 2013; 9: 375-9.
19. Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 2007; 217: 65-78.
20. Kandere-Grzybowska K, Letourneau R, Kempuraj D, et al. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J Immunol 2003; 171: 4830-6.
21. Cao J, Papadopoulou N, Kempuraj D, et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 2005; 174: 7665-75.
22. Jennings S, Russell N, Jennings B, et al. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin Immunol Pract 2014; 2: 70-6.
23. Theoharides TC, Petra AI, Stewart JM, Tsilioni I, Panagiotidou S, Akin C. High serum corticotropin-releasing hormone (CRH) and bone marrow mast cell CRH receptor expression in a mastocytosis patient. J Allergy Clin Immunol 2014; 134: 1197-9.
24. Moura DS, Georgin-Lavialle S, Gaillard R, Hermine O. Neuropsychological features of adult mastocytosis. Immunol Allergy Clin North Am 2014; 34: 407-22.
25. Rottem M, Mekori YA. Mast cells and autoimmunity. Autoimmun Rev 2005; 4: 21-7.
26. Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 2008; 8: 478-86.
27. Kounis NG. Mechanisms of acute coronary syndromes. N Engl J Med 2013; 369: 883.
28. Sokol H, Georgin-Lavialle S, Canioni D, et al. Gastrointestinal manifestations in mastocytosis: a study of 83 patients. J Allergy Clin Immunol 2013; 132: 866-73.
29. Smith JH, Butterfield JH, Pardanani A, DeLuca GC, Cutrer FM. Neurologic symptoms and diagnosis in adults with mast cell disease. Clin Neurol Neurosurg 2011; 113: 570-4.
30. Moura DS, Sultan S, Georgin-Lavialle S, et al. Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression. PLoS One 2012; 7(6): e39468.
31. Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63: 226-32.
32. van Anrooij B, van der Veer E, de Monchy JG, et al. Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis. J Allergy Clin Immunol 2013; 132: 125-30.
33. Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood 2007; 110: 2331-3.
34. Teodosio C, Mayado A, S?nchez-Mu?oz L, et al. The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis. J Leukoc Biol 2015; 97: 49-59.
35. Zanotti R, Lombardo C, Passalacqua G, et al. Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol 2015 January 17 (Epub ahead of print).
36. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603-25.
37. Cohen SS, Skovbo S, Vestergaard H, et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haematol 2014; 166: 521-8.
38. Castells M, Metcalfe DD, Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol 2011; 12: 259-70.
39. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435-53.
40. Carter MC, Metcalfe DD, Clark AS, Wayne AS, Maric I. Abnormal bone marrow histopathology in paediatric mastocytosis. Br J Haematol 2015; 168: 865-73.
41. Bodemer C, Hermine O, Palm?rini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010; 130: 804-15.
42. Alvarez-Twose I, Va-Galvn S, S?nchez-Mu?oz L, et al. Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy 2012; 67: 813-21.
43. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009; 113: 5727-36.
44. Erben P, Schwaab J, Metzgeroth G, et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 2014; 93: 81-8.
45. Hoermann G, Gleixner KV, Dinu GE, et al. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Allergy 2014; 69: 810-3.
46. Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 2002; 100: 661-5.
47. Escribano L, Alvarez-Twose I, S?nchez-Mu?oz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009; 124: 514-21.
48. Wheatley LM, Togias A. Allergic rhinitis. N Engl J Med 2015; 372: 456-63.
49. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987; 316: 1622-6.
50. Ravi A, Butterfield A, Weiler CR. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α. J Allergy Clin Immunol Pract 2014; 2: 775-8.
51. Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol 2010; 126(6): 1099.e4-1104.e4.
52. Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012; 157: 215-25.
53. Sonneck K, Florian S, Müllauer L, et al. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int Arch Allergy Immunol 2007; 142: 158-64.
54. Ribatti D. Mast cells as therapeutic target in cancer. Eur J Pharmacol 2015 Apr 24. (Epub ahead of print).
55. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006; 26: 451-63.
56. Kristensen T, Vestergaard H, M?ller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn 2011; 13: 180-8.
57. Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010; 126(3): 477.e42-480.e42.
58. Butterfield JH. Increased leukotriene E4 excretion in systemic mastocytosis. Prostaglandins Other Lipid Mediat 2010; 92: 73-6.
59. Clemons A, Vasiadi M, Kempuraj D, Kourelis T, Vandoros G, Theoharides TC. Amitriptyline and prochlorperazine inhibit proinflammatory mediator release from human mast cells: possible relevance to chronic fatigue syndrome. J Clin Psychopharmacol 2011; 31: 385-7.
60. Godt O, Proksch E, Streit V, Christophers E. Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology 1997; 195: 35-9.
61. Schoch C. In vitro inhibition of human conjunctival mast-cell degranulation by ketotifen. J Ocul Pharmacol Ther 2003; 19: 75-81.
62. Alevizos M, Karagkouni A, Vasiadi M, et al. Rupatadine inhibits inflammatory mediator release from human laboratory of allergic diseases 2 cultured mast cells stimulated by platelet-activating factor. Ann Allergy Asthma Immunol 2013; 111: 524-7.
63. Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 1990; 85: 852-5.
64. Oka T, Kalesnikoff J, Starkl P, Tsai M, Galli SJ. Evidence questioning cromolyn's effectiveness and selectivity as a 'mast cell stabilizer' in mice. Lab Invest 2012; 92: 1472-82.
65. Vieira Dos Santos R, Magerl M, Martus P, et al. Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. Br J Dermatol 2010; 162: 674-6.
66. Weng Z, Patel A, Panagiotidou S, Theoharides TC. The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J Allergy Clin Immunol 2015; 135(4): 1044.e5-1052.e5.
67. Maurer M, Ros?n K, Hsieh HJ. Omalizumab for chronic urticaria. N Engl J Med 2013; 368: 2530.
68. Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007; 119: 1550-1.
69. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004; 103: 3222-5.
70. Krauth MT, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, Valent P. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy 2009; 39: 1711-20.
71. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006; 108: 286-91.
72. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood 2003; 102: 4270-6.
73. Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004; 28: 127-31.
74. Ustun C, Reiter A, Scott BL, et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol 2014; 32: 3264-74.
75. Harvima IT, Levi-Schaffer F, Draber P, et al. Molecular targets on mast cells and basophils for novel therapies. J Allergy Clin Immunol 2014; 134: 530-44.